Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3831942 | 0.90 | SCD (0.63) | SCDDCTPP1 | |
| SCHEMBL3825767 | 0.85 | SCD (0.58) | SCDDCTPP1 | |
| SCHEMBL14130913 | 0.83 | SCD (0.56) | SCDDCTPP1 | |
| SCHEMBL3830177 | 0.83 | SCD (0.56) | SCDDCTPP1 | |
| SCHEMBL3825783 | 0.83 | SCD (0.56) | SCDDCTPP1 | |
| SCHEMBL937224 | 0.83 | SCD (0.66) | SCDDCTPP1 | |
| SCHEMBL1766107 | 0.83 | SCD (0.69) | SCDDCTPP1 | |
| SCHEMBL3845305 | 0.83 | SCD (0.66) | SCDDCTPP1 | |
| SCHEMBL935839 | 0.82 | SCD (0.77) | SCDDCTPP1 | |
| SCHEMBL3828741 | 0.81 | SCD (0.54) | SCDDCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807085-B1 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2013-08-21 | — | — | EP | disclosed |
| EP-2266569-A2 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| US-7767677-B2 | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2010-08-03 | — | — | US | disclosed |
| US-20080096895-A1 | Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-04-24 | — | — | US | disclosed |
| CN-101083994-A | Heterocyclic derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2007-12-05 | — | — | CN | disclosed |
| EP-1807085-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006034440-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096895-A1 | Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors | SCD, SCD5, ECHS1 | SCD 1/4885DCTPP1 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.